IMPACT THERAP-B(07630),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

07630 IMPACT THERAP-B

Market Closed 11-13 16:08:15

9.115

+0.725

+8.64%

High9.270	Low8.110	Vol8.93M
Open8.110	D1 Closing8.390	Amplitude13.83%
Mkt Cap2.57B	Tradable Cap2.57B	Total Shares282.46M
T/O78.62M	T/O Rate3.16%	Tradable Shares282.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"IMPACT THERAP-B","latestPrice":9.115,"timestamp":1794557295636,"preClose":8.39,"halted":0,"volume":8926600,"delay":0,"changeRate":0.08641239570917754,"floatShares":282461530,"shares":282461530,"eps":-1.294715,"marketStatus":"Market Closed","change":0.725,"latestTime":"11-13 16:08:15","open":8.11,"high":9.27,"low":8.11,"amount":78616657,"amplitude":0.13826,"askPrice":9.12,"askSize":21600,"bidPrice":9.115,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":-1.052,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":7,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":8.39,"openAndCloseTimeList":[[1794533400000,1794542400000],[1794546000000,1794556800000]],"volumeRatio":1.744853360844818,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07630/wiki","defaultTab":"wiki","newsList":[{"id":"1151777486","title":"Movement Alert｜IMPACT THERAP-B rises 6.85% in Regular Trading, buyback plan remains the clearest recent catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1151777486","media":"Market Focus","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151777486?lang=en_us&edition=fundamental","pubTime":"2026-11-13 11:01","pubTimestamp":1794538884,"startTime":"0","endTime":"0","summary":"On November 13, IMPACT THERAP-B rose 6.85% in Regular Trading, trading at HK$8.93, with turnover of HK$25.45 million.The clearest recent catalyst is the company’s previously announced H-share buyback...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"IMPACT THERAP-B surges on HK$100 million buyback plan","news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167311878","title":"IMPACT Therapeutics Launches On-Market Buyback of Up to HK$100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1167311878","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167311878?lang=en_us&edition=fundamental","pubTime":"2026-11-04 06:40","pubTimestamp":1793745646,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. disclosed on 4 November 2026 that its board has approved an on-market repurchase of H shares on the Hong Kong Stock Exchange for an aggregate consideration of up to...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170861393","title":"IMPACT THERAP-B (07630) Plans Share Buyback of Up to HK$100 Million for H Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1170861393","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170861393?lang=en_us&edition=fundamental","pubTime":"2026-11-04 06:40","pubTimestamp":1793745614,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) has announced that its board of directors has resolved to repurchase the company's H shares on the open market of The Stock Exchange of Hong Kong Limited from time to time,...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680947705","title":"Impact Therapeutics Board Authorizes Share Buyback of up to HK$ 100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2680947705","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680947705?lang=en_us&edition=fundamental","pubTime":"2026-11-04 06:39","pubTimestamp":1793745549,"startTime":"0","endTime":"0","summary":"Impact Therapeutics Board Authorizes Share Buyback of Up to HK$ 100 MillionImpact Therapeutics’ board resolved to repurchase up to HK$ 100 million of H Shares on the open market, including transaction","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nNDL16lT4H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680030857","title":"Impact Therapeutics - to Repurchase H Shares for up to Hk$100 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2680030857","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680030857?lang=en_us&edition=fundamental","pubTime":"2026-11-04 06:21","pubTimestamp":1793744465,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261103:nFWN46K2EO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170152542","title":"IMPACT THERAP-B (07630) Opens Over 3% Higher as Latest Clinical Data for Three Pipeline Drugs Including IMP4297 Debut at ESMO 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1170152542","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170152542?lang=en_us&edition=fundamental","pubTime":"2026-10-26 09:30","pubTimestamp":1792978235,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) opened more than 3% higher, rising 3.55% to HK$10.78 as of press time, with a turnover of HK$306,200.On the news front, on October 23, IMPACT THERAP-B announced that the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCAI","BK1161","BK4585","VXUS","BK4588","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677992263","title":"Impact Therapeutics Presents Results from Three Tumor Drug Studies at European Oncology Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2677992263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677992263?lang=en_us&edition=fundamental","pubTime":"2026-10-23 20:37","pubTimestamp":1792759054,"startTime":"0","endTime":"0","summary":"Impact Therapeutics  presented the latest clinical data for its pipeline drugs Senaparib, IMP1734, and IMP1707 as posters at the 2026 European Society for Medical Oncology  Congress.The data included the first-line maintenance benefit of Senaparib in advanced ovarian cancer, a Friday bourse filing showed.The results of IMP1734 and IMP1707 for the treatment of advanced solid tumors also showed favorable safety profiles.The ESMO Congress took place in Madrid, Spain, from Oct. 23 to 27.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK4007","BK1161","07630","BK4539","BK4139","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192666575","title":"IMPACT Therapeutics Showcases Positive Senaparib, IMP1734 and IMP1707 Data at 2026 ESMO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1192666575","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192666575?lang=en_us&edition=fundamental","pubTime":"2026-10-23 16:41","pubTimestamp":1792744888,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics (IMPACT) released updated clinical results for three pipeline assets—senaparib (IMP4297), IMP1734 (EIK1003) and IMP1707 (EIK1004)—during poster sessions at the European Society...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189920176","title":"IMPACT THERAP-B (07630) Presents Latest Clinical Data for Senaparib, Selective PARP1 Inhibitors IMP1734 and IMP1707 in Poster Sessions at 2026 ESMO Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=1189920176","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189920176?lang=en_us&edition=fundamental","pubTime":"2026-10-23 16:40","pubTimestamp":1792744825,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) announced that the latest clinical data for its pipeline drugs Senaparib (IMP4297), IMP1734 (also known as EIK1003), and IMP1707 (also known as EIK1004) were presented in...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140865287","title":"Movement Alert｜IMPACT THERAP-B Intraday Rise 9.03% in Regular Trading, previous Senaparib CHMP positive opinion remains a key catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=1140865287","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140865287?lang=en_us&edition=fundamental","pubTime":"2026-10-16 11:49","pubTimestamp":1792122586,"startTime":"0","endTime":"0","summary":"On October 16, IMPACT THERAP-B rose 9.03% in Regular Trading, trading at HK$14.49, with turnover of HK$42.12 million.The clearest established catalyst in publicly available information is continued...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"IMPACT THERAP-B Surges on Senaparib CHMP Positive Opinion","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108041887","title":"Movement Alert｜IMPACT THERAP-B Intraday Decline 8.07%, Profit-Taking After Senaparib European Regulatory Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=1108041887","media":"Market Focus","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108041887?lang=en_us&edition=fundamental","pubTime":"2026-10-08 14:06","pubTimestamp":1791439589,"startTime":"0","endTime":"0","summary":"On October 8, IMPACT THERAP-B fell 8.07% in regular trading, settling at HK$13.32 with turnover of HK$27.08 million. The decline reflects substantial profit-taking following a sharp prior rally, as...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Senaparib EU Milestone Sparks Profit-Taking Drop","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172148358","title":"IMPACT THERAP-B Maintains Stable Share Base and Public Float Compliance in September 2026 Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1172148358","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1172148358?lang=en_us&edition=fundamental","pubTime":"2026-10-05 17:04","pubTimestamp":1791191096,"startTime":"0","endTime":"0","summary":"IMPACT Therapeutics, Inc. (IMPACT THERAP-B) reported no changes to its authorised or issued share capital for the month ended 30 September 2026, according to the company’s latest Monthly Return filed...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133743474","title":"Movement Alert｜IMPACT THERAP-B Rises 8.26% in Regular Trading, Senaparib European CHMP Approval Catalyst Continues to Drive Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1133743474","media":"Market Focus","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133743474?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:32","pubTimestamp":1790659945,"startTime":"0","endTime":"0","summary":"On September 29, IMPACT THERAP-B rose 8.26% in regular trading, reaching HKD 14.03 before trading at HKD 14.17, with turnover of HKD 62.75 million. The stock staged a rebound after a prior pullback...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"IMPACT THERAP-B Gains on CHMP Positive Opinion for Senaparib","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196903490","title":"Movement Alert｜IMPACT THERAP-B Falls 8.05% in Regular Trading, Profit-Taking After Recent Surge Compounded by Biotech Sector Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=1196903490","media":"Market Focus","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196903490?lang=en_us&edition=fundamental","pubTime":"2026-09-24 10:12","pubTimestamp":1790215962,"startTime":"0","endTime":"0","summary":"On September 24, IMPACT THERAP-B fell 8.05% in regular trading, trading at HK$13.94 per share, with turnover of approximately HK$38.79 million. The decline came after a period of sharp gains driven...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Biotech Selloff Hits IMPACT THERAP-B After EU CHMP Nod","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122246350","title":"Hong Kong Equities Close Higher | Hang Seng Index Regains 25,000 Mark, Innovative Drug Shares Rally Broadly, SBP Group Tops Blue-Chip Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=1122246350","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122246350?lang=en_us&edition=fundamental","pubTime":"2026-09-21 16:39","pubTimestamp":1789979997,"startTime":"0","endTime":"0","summary":"Hong Kong's three major stock indices trended upward in a choppy session on Monday, with the Hang Seng Index reclaiming the 25,000-point level. By the close, the Hang Seng Index rose 1.18%, or 291.93...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","MEDX","BK1574","09115","BK1240","01177","BK1109","HK0000165453.HKD","07300","BK1589","IE00BZ08YT58.USD","VXUS","83115","07630","BK4585","LNGR","06978","BK1161","06727","BK1521","HSImain","01477","BK1535","IE00BZ08YR35.GBP","07500","01918","BK4588","IBBQ","SG9999014674.SGD","BK1555","03419","02800","513600","HSI","03037","03115","KCAI","MCHmain","BK1166","IE00BZ08YS42.EUR","02833","82800","BK1515","HHImain","MHImain","159992","01138","07200"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186138913","title":"IMPACT THERAP-B Soars Over 37% as Its Drug Nears EU Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1186138913","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186138913?lang=en_us&edition=fundamental","pubTime":"2026-09-21 09:40","pubTimestamp":1789954828,"startTime":"0","endTime":"0","summary":"IMPACT THERAP-B (07630) saw a sharp rally in early trading, climbing more than 19% before paring gains to trade 12.82% higher at HK$14.70, with turnover reaching HK$37.55 million.On September 18, the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4087","BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129549047","title":"Housing Market Enters Inventory Era; MiniMax Open-Sources Code CLI - Key Overnight Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=1129549047","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129549047?lang=en_us&edition=fundamental","pubTime":"2026-09-21 07:44","pubTimestamp":1789947870,"startTime":"0","endTime":"0","summary":"Real Estate Sector Shifts to an Inventory-Driven Market, Boosting Concentration Prospects for Leading Central State-Owned EnterprisesZhang Xuetao, Director of the Real Estate Market Supervision...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1117","BK1163","BK4585","BK4588","BK1109","06727","VXUS","08646","REET","00100","03223","BK1105","BK1161","KCAI","09979","BK1148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114201316","title":"Major Milestone Achieved: European Regulators Endorse Sepalna as Impact Therapeutics-B (07630) Surges 15.51% at Close","url":"https://stock-news.laohu8.com/highlight/detail?id=1114201316","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114201316?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:28","pubTimestamp":1789730898,"startTime":"0","endTime":"0","summary":"Shares of innovative drugmaker Impact Therapeutics-B (07630) experienced a strong rally on September 18, closing at HK$13.03, a rise of HK$1.75 or 15.51% from the previous trading day.The stock...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668928894","title":"Impact Therapeutics Gets Positive EMA Opinion for Ovarian Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2668928894","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668928894?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:14","pubTimestamp":1789730092,"startTime":"0","endTime":"0","summary":"Impact Therapeutics  said the European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of Senaparib as a maintenance treatment for advanced ovarian, fallopian tube and primary peritoneal cancer.The recommendation is based mainly on results from the Phase III FLAMES trial, the company said in a Friday Hong Kong bourse filing. The drug will now be submitted to the European Commission for a final decision. If approved, Senaparib will be authorized for marketing across European Union member states and European Economic Area countries.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","BK1161","LENZ","BK4007","07630","EPV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668940382","title":"Impact Therapeutics - Senaparib Submitted to European Commission for Final Marketing Authorization Decision","url":"https://stock-news.laohu8.com/highlight/detail?id=2668940382","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668940382?lang=en_us&edition=fundamental","pubTime":"2026-09-18 18:48","pubTimestamp":1789728491,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nFWN45A09L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.impacttherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":-0.3157},{"period":"3month","weight":-0.2901},{"period":"6month","weight":-0.7724},{"period":"1year","weight":-0.5465},{"period":"ytd","weight":-0.5465}],"compareEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.0278},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0896},{"period":"1year","weight":-0.1269},{"period":"ytd","weight":-0.0778}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"IMPACT Therapeutics Inc is a China-based company mainly engaged in biotechnology research and commercialization. The Company is in the commercialization stage. The Company is committed to advancing synthetic lethality (SL)-based precision anti-cancer therapies globally. The Company's independently developed core product, senaparib, in China as a 1L maintenance therapy for ovarian cancer (OC). The Company is currently developing product pipeline packages such as PARP1/2, PARP1, ATR, WEE1, PKMYT1/WEE1, DHX9, ATM, USP1, and CHK1/2.","exchange":"SEHK","name":"IMPACT THERAP-B","nameEN":"IMPACT THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"IMPACT THERAP-B(07630),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest IMPACT THERAP-B(07630) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"IMPACT THERAP-B,07630,IMPACT THERAP-B股票,IMPACT THERAP-B股票老虎,IMPACT THERAP-B股票老虎国际,IMPACT THERAP-B行情,IMPACT THERAP-B股票行情,IMPACT THERAP-B股价,IMPACT THERAP-B股市,IMPACT THERAP-B股票价格,IMPACT THERAP-B股票交易,IMPACT THERAP-B股票购买,IMPACT THERAP-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"IMPACT THERAP-B(07630),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest IMPACT THERAP-B(07630) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}